Literatur
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686
Aringer M, Smolen JS (2006) Systemic lupus erythematosus – activity and outcome. Z Rheumatol 65:103–109
Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69:1269–1274
Aringer M, Hiepe F (2011) Systemic lupus erythematosus. Z Rheumatol 70:313–323
Fischer-Betz R, Schneider M (2013) Recommendation for use of belimumab for systemic lupus erythematosus. Z Rheumatol 72:462–467
Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782
Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530
Houssiau FA, Vasconcelos C, D’Cruz D et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61–64
Aringer M, Fischer-Betz R, Hiepe F (2013) Statement on the use of mycophenolate mofetil for systemic lupus erythematosus. Z Rheumatol 72:575–580
Fischer-Betz R, Chehab G, Sander O et al (2012) Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol 39:2111–2117
Aringer M, Fischer-Betz R, Hiepe F (2013) Statement on the use of mycophenolate mofetil for systemic lupus erythematosus. Z Rheumatol 72:575–580
Aringer M, Burkhardt H, Burmester GR et al (2012) Current state of evidence on ‚off-label‘ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. Lupus 21:386–401
Einhaltung ethischer Richtlinien
Interessenkonflikt. Die Autoren weisen auf folgende Beziehungen hin: M. Aringer: Advisory Boards und Vorträge GlaxoSmithKline (GSK) sowie Advisory Boards Roche. M. Schneider: Advisory Boards und Vorträge GlaxoSmithKline (GSK). Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aringer, M., Schneider, M. Kochrezepte Systemischer Lupus erythematodes. Z. Rheumatol. 73, 496–500 (2014). https://doi.org/10.1007/s00393-013-1324-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-013-1324-5